In a report issued on March 10, Justin Zelin from BTIG maintained a Buy rating on Poseida Therapeutics (PSTX – Research Report), with a price target of $40.00. The company’s shares closed last Friday at $4.76.
According to TipRanks.com, Zelin has 0 stars on 0-5 stars ranking scale with an average return of -11.9% and a 30.5% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Surface Oncology, and Legend Biotech.
Poseida Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $32.00.
The company has a one-year high of $11.56 and a one-year low of $3.10. Currently, Poseida Therapeutics has an average volume of 157.5K.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PSTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
Read More on PSTX: